Physician profile
John D Serfas
NPI 1508203761
$30,707.75
in general payments reported to CMS, 2019-2025
25 companies · $392 in 2025
The $392 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.48 · 2020: $117 · 2021: $24K · 2022: $1,268 · 2023: $3,386 · 2024: $1,630 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,741 · Grant: $2,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,741.09 |
| Grant | $2,667.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $20,959.81 | 2021-2024 | Resolute Onyx, Harmony |
| Abbott Laboratories | $7,098.20 | 2021-2024 | Xience Skypoint, Piccolo Xpress |
| Edwards Lifesciences Corporation | $1,079.14 | 2022-2024 | Pascal |
| Medtronic Vascular, INC. | $181.01 | 2019-2020 | |
| Boston Scientific Corporation | $169.33 | 2022-2025 | General - Atherectomy |
| W. L. Gore & Associates, INC. | $165.04 | 2024 | Gore Cardioform Septal Occluder |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $149.09 | 2024-2025 | Lifevest |
| Cardiva Medical, INC. | $126.24 | 2024 | Cardiva Vascade 6/7f Vcs |
| Philips North America LLC | $108.07 | 2024 | (Ao0) Igt Devices Intracardiac |
| Ge Healthcare | $100.21 | 2022 | |
| B. Braun Interventional Systems INC. | $86.97 | 2023 | Cp Stent |
| Penumbra, INC. | $86.79 | 2024-2025 | Ruby Coil |
| Novo Nordisk INC | $80.05 | 2024-2025 | Wegovy |
| Pfizer INC. | $49.61 | 2024-2025 | |
| Cathworks, INC. | $44.96 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $42.63 | 2023-2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $38.10 | 2025 | Camzyos |
| Sanofi-Aventis U.S. LLC | $27.55 | 2024 | |
| Amgen INC. | $21.07 | 2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.91 | 2024 | Jardiance |
| Cook Medical LLC | $15.98 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $15.74 | 2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $14.89 | 2024 | Farxiga |
| Scpharmaceuticals INC. | $14.63 | 2024 | |
| Cordis US Corp. | $13.73 | 2024 | Mynx Control |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Serfas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.